300347 泰格医药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.8659.97210.64316.78717.202
总资产报酬率 ROA (%)2.7137.0897.84013.29212.943
投入资产回报率 ROIC (%)3.1568.2779.11015.26415.416

边际利润分析
销售毛利率 (%)38.88038.57739.63743.55347.435
营业利润率 (%)21.41033.68036.44670.91169.615
息税前利润/营业总收入 (%)22.07032.23534.25766.52372.261
净利润/营业总收入 (%)17.82229.11632.06265.05663.560

收益指标分析
经营活动净收益/利润总额(%)95.76873.53474.60942.76734.769
价值变动净收益/利润总额(%)6.87627.76524.70157.74664.076
营业外收支净额/利润总额(%)0.1900.0640.115-0.337-0.162

偿债能力分析
流动比率 (X)1.3652.7412.9784.49810.222
速动比率 (X)1.3612.7352.9724.49510.218
资产负债率 (%)19.34817.61117.36313.2090.084
带息债务/全部投入资本 (%)17.17014.35313.7117.7993.430
股东权益/带息债务 (%)467.626578.707604.9151,136.8152,729.354
股东权益/负债合计 (%)359.606402.258410.935577.926978.316
利息保障倍数 (X)35.652-21.973-15.350-16.03026.198

营运能力分析
应收账款周转天数 (天)66.65155.78646.66544.88588.281
存货周转天数 (天)1.9871.8101.1910.6620.636